Substituted benzamides and methods of use thereof
US-2016340309-A1 · Nov 24, 2016 · US
US10174008B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10174008-B2 |
| Application number | US-201515545858-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 3, 2015 |
| Priority date | Dec 3, 2014 |
| Publication date | Jan 8, 2019 |
| Grant date | Jan 8, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Methods of making indole analogs using a rhodium-containing catalyst are described, along with methods of using the compounds to treat hyperglycemic, hyperlipidemic, or autoimmune disorders in mammals, and corresponding pharmaceutical compositions. Disclosed herein is a method of making indoles. The method comprises contacting a reactant of formula I wherein E is a protecting group, —SO2-Aryl, or —SO2-substituted-Aryl; and R and R2 are independently selected from the group consisting of hydrogen, halo, C1-C12-alkyl and aryl; with a rhodium(1)-containing catalyst.
Opening claim text (preview).
What is claimed is: 1. A method of making indoles, the method comprising: contacting a reactant of formula I: wherein E is a protecting group, —SO 2 -Aryl, or —SO 2 -substituted-Aryl; and R 1 and R 2 are independently selected from the group consisting of hydrogen, halo, C 1 -C 12 -alkyl, and aryl; with a rhodium(I)-containing catalyst, in the presence or absence of an alkene-containing co-reactant, for a time and at a temperature to yield a product mixture comprising a compound selected from the group consisting of formula (II), (III), and (IV): wherein R 1 , R 2 , and E are as defined previously, and R 3 is hydrogen in the absence of the alkene-containing co-reactant, and R 3 is a substituent corresponding to the alkene-containing co-reactant in the presence of the alkene-containing co-reactant. 2. The method of claim 1 , which yields a product mixture comprising a compound of formula (II). 3. The method of claim 1 , which yields a product mixture comprising a compound of formula (III). 4. The method of claim 1 , which yields a product mixture comprising a compound of formula (IV). 5. The method of claim 1 , conducted in the absence of the alpha-alkene-containing co-reactant. 6. The method of claim 1 , wherein the alkene-containing co-reactant is present and is selected from the group consisting of: wherein R 4 , R 5 , and R 6 are each independently selected from the group consisting of hydrogen, C 1 -C 12 -alkyl, C 1 -C 12 -alkyloxy, C 1 -C 12 -haloalkyl, and C 1 -C 12 -hydroxyalkyl; and E is a protecting group. 7. The method of claim 1 , wherein the rhodium(I)-containing catalyst comprises [Rh(CO) 2 Cl] 2 . 8. The method of claim 7 , which yields a product mixture comprising a compound of formula (II). 9. The method of claim 7 , which yields a product mixture comprising a compound of formula (III). 10. The method of claim 7 , which yields a product mixture comprising a compound of formula (IV). 11. The method of claim 7 , conducted in the absence of the alpha-alkene-containing co-reactant. 12. The method of claim 7 , wherein the alkene-containing co-reactant is present and is selected from the group consisting of: wherein R 4 , R 5 , and R 6 are each independently selected from the group consisting of hydrogen, C 1 -C 12 -alkyl, C 1 -C 12 -alkyloxy, C 1 -C 12 -haloalkyl, and C 1 -C 12 -hydroxyalkyl; and E is a protecting group. 13. The method of claim 1 , wherein the reactant of formula I is contacted with the catalyst in the presence of carbon monoxide. 14. The method of claim 13 , which yields a product mixture comprising a compound of formula (II). 15. The method of claim 13 , which yields a product mixture comprising a compound of formula (III). 16. The method of claim 13 , which yields a product mixture comprising a compound of formula (IV). 17. The method of claim 13 , conducted in the absence of the alpha-alkene-containing co-reactant. 18. The method of claim 13 , wherein the alkene-containing co-reactant is present and is selected from the group consisting of: wherein R 4 , R 5 , and R 6 are each independently selected from the group consisting of hydrogen, C 1 -C 12 -alkyl, C 1 -C 12 -alkyloxy, C 1 -C 12 -haloalkyl, and C 1 -C 12 -hydroxyalkyl; and E is a protecting group. 19. A method of treating hyperglycemic, hyperlipidemic, or autoimmune disorders in mammals, wherein the autoimmune disorders are selected from the group consisting of arthritis, multiple sclerosis, psoriasis, and inflammatory bowel disease, the method comprising administering to a mammal an anti-hyperglycemic-effective, anti-hyperlipidemic-effective, or anti-autoimmune-effective amount of one or more compounds selected from the group consisting of: wherein R 1 and R 2 are independently selected from the group consisting of hydrogen, halo, C 1 -C 12 -alkyl, and aryl; and R 3 is selected from the group consisting of: wherein R 4 , R 5 , and R 6 are each independently selected from the group consisting of hydrogen, C 1 -C 12 -alkyl, C 1 -C 12 -alkyloxy, C 1 -C 12 -haloalkyl, and C 1 -C 12 -hydroxyalkyl; E is a protecting group or a hydrogen atom; or a pharmaceutically suitable salt thereof. 20. A pharmaceutical composition for treating hyperglycemic, hyperlipidemic, or autoimmune disorders in mammals, wherein the autoimmune disorders are selected from the group consisting of arthritis, multiple sclerosis, psoriasis, and inflammatory bowel disease, the composition comprising an anti-hyperglycemic-effective, anti-hyperlipidemic-effective, or anti-autoimmune-effective amount of one or more of the compounds selected from the group consisting of: wherein R 1 and R 2 are independently selected from the group consisting of hydrogen, halo, C 1 -C 12 -alkyl, and aryl; and R 3 is selected from the group consisting of: wherein R 4 , R 5 , and R 6 are each independently selected from the group consisting of hydrogen, C 1 -C 12 -alkyl, C 1 -C 12 -alkyloxy, C 1 -C 12 -haloalkyl, and C 1 -C 12 -hydroxyalkyl; E is a protecting group or a hydrogen atom; or a pharmaceutically suitable salt thereof; in combination with a pharmaceutically suitable carrier.
Introduction of protecting groups or activating groups, not provided for in the preceding groups · CPC title
Cyclisation · CPC title
containing rhodium · CPC title
Carbenes or carbynes, i.e.(image) · CPC title
Cyclopropanations · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.